Ling Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ling Guo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bin Wang
Department of Anesthesiology, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu, China
1 shared publication Chu-Chu Du
Department of Anesthesiology, the First Affiliated Hospital of Wannan Medical College, Wuhu, China
1 shared publication- Hao Wang
Department of Anesthesiology, the First Affiliated Hospital of Wannan Medical College, Wuhu, China
1 shared publication - Wei Chen
Department of Anesthesiology, the First Affiliated Hospital of Wannan Medical College, Wuhu, China
1 shared publication - Yongquan Chen
Department of Anesthesiology, The First Affiliated Hospital of Wannan Medical University, Yijishan Hospital, Wuhu, China
1 shared publication - Yu-Long Wang
Department of Anesthesiology, the First Affiliated Hospital of Wannan Medical College, Wuhu, China
1 shared publication
Latest Publications
- Open Access
- 12 February 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Fluid responsiveness-guided individualized strategy for preventing hypotension after spinal anesthesia in cesarean delivery: a randomized trial of prehydration versus norepinephrine preinfusion
Objective: This study aimed to evaluate the efficacy of fluid responsiveness-guided strategies for preventing spinal anesthesia-induced hypotension (SAIH) in parturients undergoing cesarean delivery, comparing prophylactic fluid loading with norepinephrine infusion. Methods: In this fluid responsiveness-based stratified randomized controlled trial, eligible parturients were stratified into fluid responsive (FR(+)) and non-fluid responsive (FR(-)) cohorts according to carotid corrected flow time (FTc). Each stratum had a preset sample size of 236, and within each stratum, participants were randomly assigned to receive either prophylactic colloid infusion (Co) or norepinephrine infusion (NE), ultimately forming four subgroups: FR(+)/Co, FR(+)/NE, FR(-)/Co, and FR(-)/NE.Primary outcomes included the incidence of SAIH and maximum reduction in mean arterial pressure (MAP). Secondary outcomes encompassed neonatal umbilical cord blood gas analysis, Apgar scores, intraoperative hemodynamic changes, and postoperative recovery parameters. Results: Among fluid-responsive parturients, prophylactic fluid loading (FR(+)/Co) and norepinephrine infusion (FR(+)/NE) demonstrated comparable efficacy in preventing SAIH (16.7% vs. 15.1%, P > 0.05). In contrast, non-fluid-responsive parturients receiving fluid loading (FR(-)/Co) had a significantly higher SAIH incidence (34.2%) compared to those receiving norepinephrine (FR(-)/NE, 13.6%, P = 0.0004). Neonatal umbilical cord blood lactate levels were higher in the FR(+)/NE group compared to the FR(+)/Co group (1.66 ± 0.25 mmol/L vs. 1.55 ± 0.28 mmol/L, P = 0.006), suggesting potential fetal hypoxia. Additionally, the FR(+)/NE group exhibited prolonged postoperative gastrointestinal recovery times compared to the FR(+)/Co group (29 [20, 39] h vs. 24 [16, 35] h, P = 0.0438). Conclusion: Fluid loading is optimal for fluid-responsive parturients, whereas norepinephrine infusion is superior for non-fluid-responsive parturients. These findings advocate for fluid responsiveness-guided individualized SAIH prevention strategies to optimize maternal and neonatal outcomes. Trial registration: This trial was prospectively registered at ClinicalTrials.gov (ChiCTR2400084392) on May 15, 2024, prior to participant enrollment.
- 12 February 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessFluid responsiveness-guided individualized strategy for preventing hypotension after spinal anesthesia in cesarean delivery: a randomized trial of prehydration versus norepinephrine preinfusion
Objective: This study aimed to evaluate the efficacy of fluid responsiveness-guided strategies for preventing spinal anesthesia-induced hypotension (SAIH) in parturients undergoing cesarean delivery, comparing prophylactic fluid loading with norepinephrine infusion. Methods: In this fluid responsiveness-based stratified randomized controlled trial, eligible parturients were stratified into fluid responsive (FR(+)) and non-fluid responsive (FR(-)) cohorts according to carotid corrected flow time (FTc). Each stratum had a preset sample size of 236, and within each stratum, participants were randomly assigned to receive either prophylactic colloid infusion (Co) or norepinephrine infusion (NE), ultimately forming four subgroups: FR(+)/Co, FR(+)/NE, FR(-)/Co, and FR(-)/NE.Primary outcomes included the incidence of SAIH and maximum reduction in mean arterial pressure (MAP). Secondary outcomes encompassed neonatal umbilical cord blood gas analysis, Apgar scores, intraoperative hemodynamic changes, and postoperative recovery parameters. Results: Among fluid-responsive parturients, prophylactic fluid loading (FR(+)/Co) and norepinephrine infusion (FR(+)/NE) demonstrated comparable efficacy in preventing SAIH (16.7% vs. 15.1%, P > 0.05). In contrast, non-fluid-responsive parturients receiving fluid loading (FR(-)/Co) had a significantly higher SAIH incidence (34.2%) compared to those receiving norepinephrine (FR(-)/NE, 13.6%, P = 0.0004). Neonatal umbilical cord blood lactate levels were higher in the FR(+)/NE group compared to the FR(+)/Co group (1.66 ± 0.25 mmol/L vs. 1.55 ± 0.28 mmol/L, P = 0.006), suggesting potential fetal hypoxia. Additionally, the FR(+)/NE group exhibited prolonged postoperative gastrointestinal recovery times compared to the FR(+)/Co group (29 [20, 39] h vs. 24 [16, 35] h, P = 0.0438). Conclusion: Fluid loading is optimal for fluid-responsive parturients, whereas norepinephrine infusion is superior for non-fluid-responsive parturients. These findings advocate for fluid responsiveness-guided individualized SAIH prevention strategies to optimize maternal and neonatal outcomes. Trial registration: This trial was prospectively registered at ClinicalTrials.gov (ChiCTR2400084392) on May 15, 2024, prior to participant enrollment.